Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Terence Flynn – Lazard Capital Markets.
Terence C. Flynn – Lazard Capital Markets
First on 3454, just wondering if you can share with us any additional details of the potential design of the Alzheimer’s disease trial and possibly when you might, or Roche might initiate that study.
Vaughn Kailian
Well first of all when that program, and that aspect of the program went over to Roche that basically is Roche’s responsibility to handle all further disclosures on the AD trial. I don’t believe that we’re at liberty to discuss that beyond what we’ve already said that we expected to start in the near future here.
Our responsibility is to complete the CIAS trial and the biomarker studies that we’ve just talked about and the 908 trial. So, we’ll be pretty expansive about the results of those trials since they’re within in our domain, but the other trials and the future plans for 3454 you’re probably going to have to ask the folks at Roche. Suffice it to say, I think they’re very excited about the program.
Terence C. Flynn – Lazard Capital Markets
So we shouldn’t expect a press release from you guys once Roche starts that study, like if Roche elects not to disclose it for some reason just given its an earlier stage program you guys -
Vaughn Kailian
That’s a good question. Why don’t we ask Jzaneen and Steve?
Michael Smith
This is Mike Smith. Yes, we will be announcing the details of that study once the study becomes basically initiates, but at this time for confidentiality and competitive reasons, those are things that we can’t disclose. Well we have disclosed the Phase II study in AD.
Terence C. Flynn – Lazard Capital Markets
And just on 63908, I know you’re still going through the Phase Ia data and we’re going to get this shortly, but just wondering assuming there are no safety signals, what the next steps for that program would be with respect to a Phase II study or Phase Ib?
Vaughn Kailian
Steve?
Stephen Murray
This is Steve Murray. Like with 3454, Roche will take responsibility for 63908 as it moves forward. We will have the data, as we said later this quarter for the Phase I program, but the planning for additional studies will have to be announced by Roche.
Terence C. Flynn – Lazard Capital Markets
- To read the full transcript on Seeking Alpha, click here »
